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Controversy surrounds the question of whether clinical trial participants have better outcomes than com-
parable patients who are not treated on a trial. We explored this question using a recent large, randomized,
multicenter study comparing peripheral blood (PB) with bone marrow transplantation from unrelated do-
nors, conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). We compared
characteristics and outcomes of study participants (n ¼ 494) and nonparticipants (n ¼ 1384) who appeared
eligible and received similar treatment without enrolling on the BMT CTN trial at participating centers during
the study time period. Data were obtained from the Center for International Blood and Marrow Transplantdgments on page 1821.
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N. Khera et al. / Biol Blood Marrow Transplant 21 (2015) 1815e18221816Research. Outcomes were compared between the 2 groups using Cox proportional hazards regression models.
No signiﬁcant differences in age, sex, disease distribution, race/ethnicity, HLA matching, comorbidities, and
interval from diagnosis to hematopoietic cell transplantation were seen between the participants and non-
participants. Nonparticipants were more likely to have lower performance status, lower risk disease, and
older donors, and to receive myeloablative conditioning and antithymocyte globulin. Nonparticipants were
also more likely to receive PB grafts, the intervention tested in the trial (66% versus 50%, P < .001). Overall
survival, transplantation-related mortality, and incidences of acute or chronic graft-versus-host disease were
comparable between the 2 groups though relapse was higher (hazard ratio, 1.22; 95% conﬁdence interval, 1.02
to 1.46; P ¼ .028) in nonparticipants. Despite differences in certain baseline characteristics, survival was
comparable between study participants and nonparticipants. The results of the BMT CTN trial appear
generalizable to the population of trial-eligible patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION 350 transplantation centers worldwide contribute detailed data on
Randomized clinical trials (RCT) are considered the gold
standard in clinical research. However, their applicability to
larger populations may be limited because trial patients may
not be representative of most patients because of selection
bias [1]. Despite this potential limitation, very few trials have
the generalizability of their results assessed, even though
discussion about generalizability is a quality indicator for
RCT reporting within the Consolidated Standards of Report-
ing Trials guidelines [2]. It is also controversial whether pa-
tients enrolled in trials have better outcomes than those not
enrolled in trials, controlling for biological characteristics.
Although some studies show improved outcomes in trial
participants compared with nonparticipants [3-6], others
report no trial effect [7,8]. Peppercorn et al. reported that
most studies comparing outcomes between trial and nontrial
participants failed to control for potential confounding fac-
tors between the groups, and, therefore, available evidence
does not support a trial effect on outcomes [9].
The Blood and Marrow Transplant Clinical Trials Network
(BMT CTN) conducts multicenter trials to improve treatment
approaches in hematopoietic cell transplantation (HCT). A
phase III randomized, multicenter study conducted by BMT
CTN (BMT CTN 0201) between March 2004 and September
2009 compared outcomes after bone marrow (BM) and
ﬁlgrastim-mobilized peripheral blood (PB) HCT from unre-
lated donors (URD) [10]. The trial found no signiﬁcant dif-
ference in survival between the 2 groups, but it found a
signiﬁcant increase in the risk of chronic graft-versus-host
disease (GVHD) with PB. Its practice-changing potential is
based on the fact that the study supports the use of BM grafts
with decreased chronic GVHD, in the current era when PB is
used in 70% of URD transplantations.
Before applying the study results to clinical practice, it is
important to understand their generalizability to the uni-
verse of potential patients. To do so, we compared the
characteristics and outcomes of participants in BMT CTN
protocol 0201 with those of patients receiving URD HCTs at
the same centers during the study time period but whowere
not study participants, using data from the Center for Inter-
national Blood and Marrow Transplant Research (CIBMTR).
We restricted the analysis to centers participating in BMT
CTN and to patients receiving similar treatment off-protocol
to minimize confounding variables while assessing for a trial
effect.PATIENTS AND METHODS
Data Source
The CIBMTR is a research collaboration of the Medical College of Wis-
consin and the National Marrow Donor Program/Be The Match. More thanconsecutive allogeneic and autologous HCT to the CIBMTR’s outcomes reg-
istry. The CIBMTR also leads the data coordinating center for the BMT CTN.
Patients are followed longitudinally with yearly follow-up. Compliance is
monitored by on-site audits. Observational studies by the CIBMTR are per-
formed in compliance with the Privacy Rule (Health Insurance Portability
and Accountability Act) as a Public Health Authority and with all applicable
federal regulations pertaining to the protection of human research partici-
pants as determined by continuous review of the institutional review board
of the National Marrow Donor Program.
The current study included 2 main cohorts of patients for whom infor-
mation was retrieved from the CIBMTR database: patients treated on the
BMT CTN 0201 protocol and patients who underwent URD transplantations
during the study time period at 38 participating centers but who were not
on the BMT CTN study. The eligibility criteria for the BMT CTN protocol
included age < 66 years and HCT for acute leukemia, myelodysplasia,
chronic myeloid or myelomonocytic leukemia, or myeloﬁbrosis. Exclusion
criteria are included in Supplementary Table 1.
The comparator group of interest was patients who, based on infor-
mation from the CIBMTR database, appeared eligible per the inclusion and
exclusion criteria of the BMT CTN study and received URD HCT at the
participating centers during the time the trial was open but did not enroll in
the study. Because not all information needed to determine eligibility for the
protocol (organ function requirements) was available from the CIBMTR
database, we selected patients treated with similar regimens to identify a
group as close as possible in clinical proﬁle to the trial participants. The
assumption was that patients able to receive regimens used in the clinical
trial were likely to have organ function consistent with eligibility criteria for
the trial.
Study Outcomes
We estimated the proportion of all potentially eligible URD trans-
plantations that were enrolled on the protocol. Survival, relapse,
transplantation-related mortality (TRM), and occurrence of acute and
chronic GVHD were compared between the participants and non-
participants. TRM was deﬁned as death while in complete remission. TRM
and relapse were considered competing risks where occurrence of 1 of them
prevents occurrence of the other. Overall survival (OS) was calculated as time
from transplantation to death. Death from any cause was considered as an
event and surviving patients were censored at the time of last follow-up.
Disease-free survival (DFS) was deﬁned as time from transplantation to
treatment failure (death or relapse). Patients alive in remission were
censored at the time of last follow-up.
Statistical Analysis
The characteristics of the participants and nonparticipants in the entire
cohort and the separate PB and BM subgroups were compared using the chi-
square test for categorical variables and the Wilcoxon rank-sum test for
continuous variables. Multivariate analyses of acute and chronic GVHD, TRM,
relapse, DFS, and OS were performed using Cox proportional hazards
regression, using participation in the BMT CTN study as the main effect.
Variables considered in the multivariate analysis are described in
Supplementary Table 2. The assumption of proportional hazards was tested
for each variable using a time-dependent covariate and appropriate adjust-
mentswereperformedwhereneeded.Multivariatemodelswerebuilt using a
forward-variable selection method. In addition, stratiﬁed analysis of BM and
PB recipients was performed to compare the outcomes of BMT CTN 0201
participants versus nonparticipants within each graft source subgroup
because theproportionof graft sourcewas signiﬁcantlydifferentbetweenthe
study participants and nonparticipants. All P values are 2 sided and a level of
N. Khera et al. / Biol Blood Marrow Transplant 21 (2015) 1815e1822 1817signiﬁcance (alpha) of .05was used throughout. All analyseswere performed
using SAS Version 9.3 statistical software (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Figure 1 shows the selection of patients for this study. A
total of 5716 patients received a ﬁrst allogeneic HCT for
diseases speciﬁed by the BMT CTN 0201 protocol at
participating transplantation centers during the study
period. Among these, 2708 were excluded for not meeting
the trial eligibility criteria. We also excluded 32 partici-
pants and 109 nonparticipants from 10 centers that had no
eligible nonparticipants for analysis. An additional 6 pa-
tients were excluded because they had not consented for
CIBMTR research or had a follow-up < 100 days. From theFigure 1. Patient selecremaining 2893 patients, 1046 received a regimen
different from what was speciﬁed by the BMT CTN 0201
protocol; these patients were excluded from further anal-
ysis. Five hundred ﬁfty-one patients were enrolled on the
BMT CTN 0201 study. In addition to excluding the 32 pa-
tients from centers where comparable nontrial patients
could not be identiﬁed, we excluded 25 patients who did
not undergo HCT. The ﬁnal study population consisted of
494 patients who participated in the BMT CTN 0201 study
and 1353 patients who appeared to be eligible based on
the trial’s inclusion/exclusion criteria, did not enroll, and
yet received the same conditioning and GVHD prophylaxis
regimens as trial participants, suggesting that they
could have enrolled on the trial. Thus, approximately 27%
(494/[494 þ 1353]) of apparently eligible patients attion ﬂowchart.
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instead estimate the participation rate based on all non-
participants without regard to conditioning regimens and
GVHD prophylaxis, the trial participation rate would be
17% (494/[494 þ 1353 þ 1046]).
There were no signiﬁcant differences in the age, sex,
disease distribution, race/ethnicity, HLA matching, and in-
terval from diagnosis to HCT between the participants and
nonparticipants. A pretransplantation HCT comorbidity in-
dex, available for 64% patients, was comparable between
participants and nonparticipants. A higher proportion of
nonparticipants had a Karnofsky performance score (KPS) <
90, lower risk disease, and received antithymocyte globulin
(ATG). PB was usedmore commonly as the graft source in the
nonparticipants compared with the study participants (66%
versus 50%; P< .001) (Table 1). Characteristics of participants
and nonparticipants were also evaluated separately in the
groups receiving PB and BM. Among those receiving PB
grafts, nonparticipants were older, had more myeloid dis-
eases but comparable disease risk, higher proportion of 7/8
HLAematched donors, and more frequent use of ATG than
the study participants. In the BM group, nonparticipants
were younger, more likely to be Hispanic, have low-risk
disease, receive myeloablative conditioning and ATG, and
less likely to have a KPS  90.
Reasons for Nonparticipation
To gain insight into the reasons for nonparticipation, we
reviewed study coordinator tracking logs. We identiﬁed a
group of patients (n ¼ 713) who consented to the study but
didn’t proceed on the protocol. Among these, 344 patients
(48%) had a transplantation off protocol reported to CIBMTR.
Removal from the protocol was mainly for donor-related is-
sues (n ¼ 237, 69%); for example, the donor did not provide
consent or was ineligible for the study or because of the
donor center decision. Among patients who underwent
transplantation removed from the trial for a donor reason,
72% received PB grafts. The remaining patients (n¼ 107, 31%)
were removed because of patient-related issues (eg, patient
found to be ineligible or withdrew consent). Among these,
84% received PB grafts.
Outcomes of Participants versus Nonparticipants
Comparedwith the BMT CTN participants, nonparticipants
did not have a signiﬁcantly increased risk of mortality both in
the unadjusted analysis (P¼ .46) and after adjusting for all the
clinical variables (hazard ratio [HR], 1.08; 95% conﬁdence in-
terval [CI], .94 to 1.24, P¼ .26) (Figure 2A). Although TRMwas
comparable between the 2 groups, relapse was higher (HR,
1.22; 95% CI, 1.02 to 1.46; P ¼ .028), resulting in a trend to-
wards lower DFS in nonparticipants (HR, 1.14; 95% CI, 1.0 to
1.3; P ¼ .05). The center effect was examined and was not
found to be signiﬁcant in the multivariate model (P ¼ .11). No
statistically signiﬁcant differences in acute (HR, .96; 95% CI,
.82 to 1.12; P¼ .57) and chronic GVHD (HR,1.06; 95% CI, .92 to
1.23; P ¼ .41) were noted between study participants and
nonparticipants (Table 2).
Although the interaction between trial participation and
graft source was not signiﬁcant (P ¼ .23), we compared OS
between studyandnonstudyparticipants receivingPBandBM
separately in a secondary analysis. The risk of mortality was
not signiﬁcantlyhigher forBMrecipients (HR,1.0; 95%CI, .80 to
1.23;P¼ .94) or for PB recipients (HR,1.2; 95%CI, .98 to1.41;P¼
.07) in nonparticipants compared to trial participants.
(Figure 2B and C). A stratiﬁed analysis for other clinicaloutcomes also showed comparable results in BM and PB
groups separately in the participants and nonparticipants
(Table 3).
Impact of Graft Source
In the multivariate analysis of OS for the entire cohort,
with a median follow-up of 60 months for survivors, graft
source emerged as a signiﬁcant predictor with PB associated
with increased mortality (HR, 1.16; 95% CI, 1.01 to 1.32;
P ¼ .02). However, when the analysis was limited to 2 years
after HCT similar to the original report, no difference was
observed (HR, 1.03; 95% CI, .89 to 1.19; P ¼ .64) [10]. Similar
to the original report, PB was associated with a higher
incidence of chronic GVHD than was BM (HR, 1.38; 95% CI,
1.2 to 1.6; P < .001).
DISCUSSION
Concerns have been raised about the generalizability of
RCT results because of the questionable representation of
patients enrolled in the trials [5,11,12]. Differences in the
outcomes of patients treated on versus off trials may be due
to inclusion of a highly selected patient population (based on
medical status, disease status, or compliance), differences in
care due to clinical trial participation (eg, closer follow-up or
more precise application of therapies), or due to true bio-
logical effects [7,13,14]. Interestingly, a recent study that
compared patients on the standard arms of a series of South
West Oncology Group phase III cancer clinical trials to non-
trial control subjects selected from the Surveillance, Epide-
miology, and End Results program found that the improved
OS with trial participation was only seen for the ﬁrst year
after diagnosis and evened out in the long-term [15]. In HCT,
there is a paucity of studies evaluating if the results from
RCTs are likely to translate to the general transplantation
population.
In 1 of the ﬁrst such studies in HCT, we found that
approximately one quarter of the potentially eligible patients
participated in the randomized study. This is likely an over-
estimate, as some potentially eligible patients may have
received alternative conditioning regimens because of
competing protocols or center practices and, thus, were not
included in the denominator because of our patient selection
criteria. Even with the most conservative estimate of the
participation rate (17%), this is still much better than <10%
participation rate that has been reported in other studies
[16,17]. We observed a higher proportion of high-risk disease
in the trial participants than in the nonparticipants and
comparable distribution of age, comorbidities, and race/
ethnicity, which is also different from the pattern reported in
the literature. Usually, patients from racial/ethnic minorities
or those who are higher risk, older, and with comorbidities
are less represented in clinical trials [14,18-20]. The fact that
we did not observe this may be attributed to either the
relatively broad inclusion criteria of the clinical trial or to our
selection of comparator patients who were healthy enough
to be potential trial participants based on age and comor-
bidities. A difference between the participants and non-
participants was the greater use of ATG in the nontrial
participants, reﬂecting the standard practice of some centers
to use it outside of a clinical trial to decrease GVHDwith URD
transplantations [21,22].
Despite some differences in the clinical characteristics of
patients enrolled on the trial compared with those not
enrolled, there was no difference in the OS. This may be
because of similar baseline characteristics between the 2
Table 1
Characteristics of Patients Who Received a BM or PB Transplantation
between 2004 and 2009 from Participating Centers, according to Enrollment
Status and Regimen Received*
Characteristics Patients Enrolled
Who Underwent
Transplantation
on BMT CTN
0201 Study
Likely Eligible
but Not Enrolled,
Underwent
Transplantation
with Same
Regimen
P
Valuey
No. of patients 494 1353
Age at transplantation,
yr
.73
0-9 17 (3) 52 (4)
10-19 34 (7) 107 (8)
20-49 252 (51) 704 (52)
>50 191 (39) 490 (36)
Patient gender .18
Male 276 (56) 708 (52)
Female 218 (44) 645 (48)
Recipient race .79
Caucasian 446 (90) 1232 (91)
African-American 20 (4) 55 (4)
Other 28 (6) 66 (5)
Recipient ethnicity .06
Hispanic 19 (4) 92 (7)
Non-Hispanic 470 (95) 1250 (92)
Unknown 5 (1) 11 (<1)
KPS .03
90 313 (63) 766 (57)
<90 138 (28) 441 (33)
Unknown 43 (9) 146 (11)
Sorror comorbidity
index
.48
0 184 (37) 512 (38)
1-2 68 (14) 158 (12)
3 62 (13) 198 (15)
Unknown (info not
collected on
patients reported
before 2008)
180 (36) 485 (36)
Disease .24
AML 233 (47) 673 (50)
ALL 106 (21) 245 (18)
CML 62 (13) 150 (11)
MDS/myeloﬁbrosis/
CMML
93 (19) 285 (21)
Disease risk before
transplantationz
.02
Low risk 360 (73) 1063 (79)
High risk 134 (27) 288 (21)
Unknown 0 2 (<1)
Secondary leukemia/
MDS with prior
Auto (>12 months
from current
transplantation)
.86
No 489 (99) 1338 (99)
Yes 5 (1) 15 (1)
Graft type <.001
BM 247 (50) 456 (34)
PB 247 (50) 897 (66)
Donor age, yr <.001
18-29 200 (40) 308 (23)
30-39 154 (31) 347 (26)
40-49 114 (23) 200 (15)
50-61 26 (5) 47 (3)
Unknown 0 451 (33)
Antigen match at A, B,
DRB1
.13
8/8 371 (75) 954 (71)
7/8 123 (25) 398 (29)
Missing 0 1 (<1)
Donor/recipient sex
match
.03
M/M 208 (42) 486 (36)
(Continued)
Table 1
(continued)
Characteristics Patients Enrolled
Who Underwent
Transplantation
on BMT CTN
0201 Study
Likely Eligible
but Not Enrolled,
Underwent
Transplantation
with Same
Regimen
P
Valuey
M/F 132 (27) 399 (29)
F/M 68 (14) 214 (16)
F/F 86 (17) 239 (18)
Unknown 0 15 (1)
Donor/recipient CMV
match
<.001
/ 186 (38) 370 (27)
/þ 154 (31) 450 (33)
þ/þ 96 (19) 280 (21)
þ/ 57 (12) 154 (11)
Unknown 1 (<1) 99 (7)
Conditioning regimen
intensity
.04
Myeloablative 384 (78) 1119 (83)
Reduced intensity 110 (22) 233 (17)
Unknown 0 1 (<1)
Use of ATG or Campath <.001
ATG or Campath 126 (26) 430 (32)
No ATG or Campath 362 (73) 923 (68)
Unknown 6 (1) 0
Interval from diagnosis
to transplantation,
median (range), mo
8 (<1-168) 9 (<1-357) .49
Year of transplantation <.001
2004 30 (6) 155 (11)
2005 73 (15) 269 (20)
2006 93 (19) 275 (20)
2007 134 (27) 248 (18)
2008 103 (21) 215 (16)
2009 61 (12) 191 (14)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leu-
kemia; CML, chronic myeloid leukemia; MDS/CMML, myelodysplastic
syndrome/chronic myelomonocytic leukemia; Auto, autologous trans-
plantation; M, male; F, female; CMV, cytomegalovirus.
Data presented are n (%), unless otherwise indicated.
* Patients receiving any of the 4 conditioning regimens
(cyclophosphamide þ total body irradiation, cyclophosphamide þ busulfan,
ﬂudarabine þ busulfan þ ATG, ﬂudarabine þmelphalan) and cyclosporine/
tacrolimus þ methotrexate GVHD prophylaxis were classiﬁed as receiving
the same regimen as speciﬁed by the BMT CTN 0201 protocol; patients
receiving any other conditioning regimen or any other GVHD prophylaxis
were excluded.
y Chi-square test (for categorical variables) or Wilcoxon rank-sum test
(for continuous variables) P values between BMT CTN 0201 patients (col-
umn 1) and non-BMT CTN 0201 patients with same conditioning regimen
(column 2).
z High-risk disease includes acute myeloid leukemia in third or subse-
quent remission or not in remission, acute lymphoblastic leukemia not in
remission, the myelodysplastic syndrome with excess blasts in trans-
formation, chronic myeloid leukemia in blast phase, and chronic myelo-
monocytic leukemia in any stage. All others were considered low risk.
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ment, and HLA match, that were associated with lower OS.
Although a higher proportion of the trial nonparticipants had
lower KPS, which was associated with worse OS, this may
havebeen counterbalanced bya lower proportion of high-risk
disease. Our results are consistent with what has been re-
ported in systemic reviews: there is no deﬁnitive evidence for
superior outcomes in patients participating in a clinical trial
compared with nonparticipants treated in a similar fashion
when adjusted for the confounding factors [9,23]. In addition,
it is also possible thatHCTpatients are treated and followed in
specialized settings with aggressive supportive care, regard-
less of trial participation and leading to similar outcomes
between participants and nonparticipants.
Table 2
Multivariable Models for OS, TRM, Relapse, DFS, and GVHD
HR (95% CI) for Nonparticipants
versus Study Participants
P Value
OS* 1.08 (.94-1.24) .27
TRMy 1.08 (.8-1.29) .43
Relapsez 1.22 (1.02-1.46) .03
DFSx 1.14 (1.00-1.30) .05
Acute GVHDk .96 (.82-1.12) .58
Chronic GVHD{ 1.07 (.92-1.2) .40
* Other signiﬁcant variables include patient age, diagnosis, disease risk,
graft source, interval between diagnosis and HCT, KPS, HLA match, and
donor-recipient sex match.
y Other signiﬁcant variables include patient age, disease risk, HLA match,
donor-recipient sex match, GVHD prophylaxis, and use of ATG/
alemtuzumab.
z Other signiﬁcant variables include disease risk, donor-recipient sex
match, interval between diagnosis and HCT, KPS, and regimen intensity.
x Other signiﬁcant variables include patient age, disease risk, HLA match,
donor-recipient sex match, interval between diagnosis and HCT, and KPS.
k Other signiﬁcant variables include graft source, HLA match, regimen
intensity, and use of ATG/alemtuzumab.
{ Other signiﬁcant variables include graft source, diagnosis, ethnicity,
donor-recipient sex match, and use of ATG/alemtuzumab.
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Figure 2. Survival curves. (A) Adjusted overall survival in all study participants and nonparticipants. (B) Adjusted overall survival in study participants and non-
participants receiving bone marrow graft. (C) Adjusted overall survival in study participants and nonparticipants receiving PB graft.
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ally better in trial participants. Analyses stratiﬁed by graft
type showed that this observation is primarily because of
increased relapse in nonparticipants compared with partic-
ipants when PB is used. It is possible that more non-
participants had unmeasured high-risk disease (such as
high-risk cytogenetics or FLT3 mutation positive) not
appropriately captured in the risk categorization used for the
BMT CTN study or the current study. Although a higher
proportion of nonparticipants received ATG, receipt of ATG
was not associated with relapse in our multivariate analysis.
Poorer survival in patients receiving PB grafts compared
with survival in those receiving BM grafts in our multivariate
analysis is different from the results of the BMT CTN study as
well as a prior observational study that reported comparable
OS between PB and BM groups, except for the good-risk
chronic myeloid leukemia patients [24]. Because this differ-
ence was not detected when the observations were limited
to 2 years, our ﬁndings may be explained by a longer period
of follow-up than the clinical study (BMT CTN 0201 is
currently analyzing their 5 year follow-up data). This does,
however, potentially add increased evidence that BM should
be the default graft source.
Our study has some limitations. By applying the inclusion
criteria and restricting the nontrial cohort to those with the
same conditioning and GVHD prophylaxis, we aimed to
create a group that was similar to the trial participants to
enhance conﬁdence in the analysis. However, it is possible
that some ineligible patients on the basis of organ function
were misclassiﬁed as potentially eligible as we did not have
detailed information about organ function. Conversely, somepatients may not have appeared potentially eligible because
they received different conditioning or GVHD prophylaxis
regimens or participated in different clinical trials, even
though they could have tolerated the treatment speciﬁed by
the trial. These biases would affect the estimate of the per-
centage of potentially eligible patients that ended up on the
trial, but in opposite directions. It is also possible that other
unmeasured differences, such as use of maintenance therapy
Table 3
Stratiﬁed Analysis for OS, TRM, Relapse, DFS, and GVHD
Outcomes HR (95% CI) for Nonparticipants versus Study
Participants; P Value
PB BM
OS 1.2 (.9-1.4); .08 1.0 (.8-1.2); .90
TRM 1.2 (.9-1.5); .20 .9 (.7-1.3); .80
Relapse 1.3 (.9-1.6); .06 1.14 (.8-1.5); .30
DFS 1.2 (.9-1.4); .10 1.06 (.8-1.3); .60
Acute GVHD .9 (.8-1.2); .90 .9 (.7-1.8); .60
Chronic GVHD 1.2 (.9-1.4); .10 .9 (.7-1.2); .60
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these were not speciﬁed in the BMT CTN 0201 protocol
either. We also did not study patients who received their
URD transplants at nonstudy centers, thereby precluding a
truly population-based comparison and focusing only on the
“trial effect” aspect of generalizability. Other facets of
generalizability, including the difference in outcomes be-
tween patients treated in a similar fashion at study centers
versus at nonstudy centers, will be addressed in subsequent
analyses. We do not know the reasons for low trial enroll-
ment, such as refusal to participate, investigators not offering
the trial to patients, or enrollment on competing protocols,
because of lack of information for trial nonparticipation. By
restricting the treatment regimens to those speciﬁed by the
study, we were able to select nontrial participants who
appeared the most comparable to trial participants based on
known characteristics.
The strength of our study is thatwewere able to perform a
careful comparison of patients who did or did not participate
in the trial at the same centers treated in a similar fashion
during the same time period using a consistent data source.
This analysis improves our conﬁdence that treatment effects
for this particular trial translate to the real-world setting and
can be extrapolated to future patients who meet the disease
and health requirements outlined in the trial.
Although consideration of external validity in the design
and reporting of randomized clinical trials is important, not
all studies can do this. Our study was possible because of the
availability of the CIBMTR database, which provides a unique
resource of observational data to address questions about the
generalizability of HCTclinical trials. Such a database can also
track real-world use of technologies to understand shifts in
clinical practice. RCTs are unique in providing an unbiased
comparison of therapies but are logistically difﬁcult and
expensive. Gathering the data to support the generalizability
of clinical trial results and the actual effectiveness of study
interventions in practicewill help translate the investment in
time- and resource-intensive studies into clinical practice
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